Head of OCNI
Subita Balaram Kuttikkatte
Dr Søren Færgeman M.D. DPhil Student
After having received his MD from Aarhus University in 2013, Søren Færgeman obtained basic clinical training in internal medicine and surgery at The National Hospital of the Faroe Islands, thus acquiring the license to practice medicine in Denmark. Since then, he has worked as a clinician at The Department of Clinical Neurology, Aarhus University Hospital in Denmark, before joining Lars Fugger's lab as D.Phil. student in October 2014.
Medical school sparked an interest in clinical neurosciences, which in 2010 led to his research on the role of potassium channels and aquaporins in multiple sclerosis under the supervision of Professor Lars Fugger, University of Oxford and Professor Jørgen Frøkiær, Aarhus University Hospital. Søren's D.Phil. project focused on the role of rare genetic variants in the development of multiple sclerosis.
Dr Calli Dendrou Ph.D. 2010-2017. Postdoc and Senior Postdoctoral Fellow
After completing her degree in 2009 she joined the laboratory of Prof Lars Fugger as a postdoctoral researcher to investigate how the data explosion arising from advances in genomics can be converted into clinically relevant information - in particular through comparative analyses across different diseases. To date this has led to the first study demonstrating that elucidating the functional impact of disease-associated genetic variation can have important implications for predicting clinical outcome. Calli won the Thomas Willis Early Career Researcher Prize in 2013 and the Oxford Multiple Sclerosis Young Investigator Award in 2014.
In 2017 Calli moved to the Henry Wellcome Building of Genomic Medicine to begin her career as a PI. The key research interests of her group are to better understand the architecture of genetic predisposition across different autoimmune and immune-mediated diseases, and to explore the functional relevance and potential clinical utility of such cross-comparisons.
Dr Lydia Shipman, D.Phil. 2009-2013. D.Phil. Student
Dr Shipman was introduced to cell biology and immunophenotyping techniques that were used to address the biological implications of an MS-protective genetic variant. Dr Shipman is now a senior copy editor at Nature Reviews Immunology, London, UK.
Dr Aiden Haghikia MD, Ph.D. 2010-2012. Postdoctoral Fellow
Dr Haghikia learned molecular biology and next generation sequencing techniques relating to the investigation of drug-dependent side effects in MS. Dr Haghikia is currently a consultant neurologist and associate professor at Ruhr University Bochum, Germany.
Dr Adam P. Gregory, D.Phil. 2009-2012. D.Phil. Student
Dr Gregory was introduced to a range of different molecular and cellular biology techniques relating to the demonstration of a striking parallel between the functional consequences of an MS risk variant and a failed clinical trial in MS. Dr Gregory is a patent law assistant at Mewburn Ellis LLP, Manchester, UK.
Dr Sandra Vergo, D.Phil. 2006-2011. D.Phil. Student and Postdoctoral Fellow
Dr Vergo was introduced to the use of transgenic mouse models and learnt how to perform extensive immunohistochemical analysis of CNS tissue, in the context of a drug repositioning strategy that targeted the neurodegenerative phase of MS. Since then Dr Vergo has worked as a researcher at Novo Nordisk A/S and is now a senior research scientist at Lundbeck A/S, Denmark.
Dr Ruth Etzensperger, D.Phil. 2005-2011. D.Phil. Student and Postdoctoral Fellow
Dr Etzensperger was introduced to molecular immunology with emphasis on MS. She learned how to generate humanized mouse models of MS and how to analyse them in clinical, immunological and histopathological terms. Dr Etzensperger is a postdoctoral fellow at the NCI, NIH, USA.
Prof Dr Manuel A. Friese, MD, Ph.D. 2004-2008. Postdoctoral Fellow
Prof Dr Friese learned how to generate and utilize humanized mice as models for MS. He used these mice to address how MS associated risk genes confer risk to MS through their action on the inflammatory and the neurodegenerative arms of the disease. Prof Dr Friese is a professor of neuroimmunology and a consultant neurologist at the Clinical MS Research Center, University-Hospital Hamburg-Eppendorf, Germany.
Dr Jon W. Gregersen, MD, Ph.D. 2001-2005. Ph.D. Student
Dr Gregersen learned how to generate and utilize humanized mice as models for MS to assess functional epistasis on an MS-associated MHC haplotype. After spending some time as a clinical researcher at Addenbrooke's Hospital in Cambridge, UK, Dr Gregersen is now a lecturer at the Department of Clinical Medicine, Aarhus University, Denmark.
Dr Michelle Krogsgaard, Ph.D. 1996-1999. Ph.D. Student
Dr Krogsgaard was introduced to immunology with emphasis on MS. She learned how to generate recombinant antibodies by using the phage display technology, which she used to detect specific MHC-peptide complexes in CNS tissue. Dr Krogsgaard is an assistant professor at the NYU Langone Medical Center, New York, USA.